相关实验视频
一个随机和临床有效性试验,比较两种药物遗传算法和标准护理,用于个性化华法林剂量 (CoumaGen-II)
Jeffrey L Anderson1, Benjamin D Horne, Scott M Stevens
1Intermountain Medical Center, Cardiovascular Department, Murray, UT 84107-5701, USA. jeffrey.anderson@imail.org
Circulation
|March 21, 2012
概括
药物遗传学 (PG) 通过减少范围外的国际规范化比率和不良事件来改善华法林剂量. 一个更简单的1步PG算法与3步算法一样有效,这表明了更广泛的临床应用.
科学领域:
- 药物基因组学 药物基因组学
- 临床药理学 临床药理学
- 药物剂量优化 药物剂量优化
背景情况:
- 华法林剂量存在挑战,原因是个体的变化和狭窄的治疗窗口.
- 药物遗传学 (PG) 提供了提高华法林剂量效率和安全性的潜力.
- 目前对PG导向的华法林治疗存在有限的临床试验证据.
研究的目的:
- 为了比较两个药物遗传算法 (1 步和 3 步) 与标准华法林剂量的有效性.
- 评估药物遗传学在个性化华法林治疗中的临床实用性.
主要方法:
- 一个随机试验 (N=504) 比较了两个PG算法 (PG-1和PG-2).
- 一项临床有效性研究 (N=1866) 将PG指南与标准剂量进行了比较.
- 对CYP2C9和VKORC1进行了同一天的基因型鉴定.
- 主要结局包括范围外的国际规范化比率的百分比和治疗范围内的时间.
主要成果:
- 三步PG算法 (PG-2) 与一步PG算法 (PG-1) 没有劣势,但也没有优势.
- 与标准剂量相比,联合PG指南显著降低了范围外的国际规范化比率 (31%与1个月后42%相比;3个月后30%与42%相比).
- 在PG指导下,治疗范围的时间增加了 (69% vs. 58%在1个月; 71% vs. 59%在3个月),严重不良事件减少了 (4.5% vs. 9.4%).
结论:
- 为了更广泛的临床应用,应考虑华法林的药物遗传剂量.
- 更简单的1步PG算法证明了与3步算法同等的有效性.
- 大型随机试验的进一步验证正在进行中.
相关概念视频
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...